β‐amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease
- 25 July 2003
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 54 (2) , 263-267
- https://doi.org/10.1002/ana.10661
Abstract
Decreased levels of β‐amyloid peptide 1‐42 (Aβ1‐42) in cerebrospinal fluid (CSF) are a characteristic feature of Alzheimer's disease (AD) but recently were also observed in Creutzfeldt–Jakob disease (CJD). We analyzed the CSF of patients with CJD, and AD and nondemented controls using a quantitative urea‐based Aβ sodium dodecyl sulfate polyacrylamide gel electrophoresis immunoblot. Like in AD and nondemented controls, we found a highly conserved pattern of carboxyterminally truncated Aβ1‐37/38/39 in addition to Aβ1‐40/42 also in CJD patients. By the introduction of the ratio Aβ1‐39 to Aβ1‐42, CJD and AD can effectively be differentiated. We conclude that the immunoblot shows disease‐specific CSF Aβ peptide patterns in CJD and AD and suppose that measurement of the Aβ peptide pattern seems to be a promising diagnostic tool in the differential diagnosis of dementias. Ann Neurol 2003;54:263–267Keywords
This publication has 19 references indexed in Scilit:
- Diffusion-weighted MRI in familial Creutzfeldt–Jakob disease with the codon 200 mutation in the prion protein geneJournal of the Neurological Sciences, 2005
- Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammationJournal of Neurochemistry, 2002
- Cerebrospinal fluid τ and β-amyloid(1-42) in dementia disordersMechanisms of Ageing and Development, 2001
- Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?Journal of Neurology, Neurosurgery & Psychiatry, 2001
- Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2001
- BSE and Prions: Uncertainties About the AgentScience, 1998
- The 14-3-3 Brain Protein in Cerebrospinal Fluid as a Marker for Transmissible Spongiform EncephalopathiesNew England Journal of Medicine, 1996
- Aggregation of Secreted Amyloid β-Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell CultureJournal of Biological Chemistry, 1995
- Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal FluidJournal of Neurochemistry, 1993
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984